Time for change.
CEO has done good work!
Sentiment: Strong Buy
You are just a chart player !
You are good chart player, but finally you will lose big time.
One day you get a buyout news at $8 and then...?
"Obstructive sleep apnea, or OSA, is a chronic and potentially serious sleep disorder in which breathing is abnormally shallow, or hypopnea, or stops altogether, or apnea, for at least 10 seconds. These repetitive events are associated with collapse of the upper airway during sleep, and may occur five to thirty or more times per hour. Although many cases are unrecognized, symptoms may include snoring, fatigue or sleepiness during the day.
OSA afflicts approximately 3% to 7% of the U.S. population. Data from the Wisconsin Cohort Study indicate that the prevalence of OSA in people 30-60 years of age is 9-24% for men and 4-9% for women. OSA is associated with an increased risk of hypertension, cardiovascular disease, myocardial infarction, stroke and increased mortality.
The current standard of care treatment for OSA is continuous positive airway pressure, or CPAP, in which the upper airway is kept open by increased air pressure, but CPAP provides benefits only when used consistently. Many patients find CPAP to be inconvenient or uncomfortable, and compliance with CPAP treatment limits its effectiveness.
We believe a safe and effective pharmacologic treatment for OSA could be useful and more acceptable to some patients than CPAP, but no drug is currently approved to treat OSA.
In January 2010, we announced positive results from a Phase 2 study evaluating the safety and efficacy of Qsymia for the treatment of moderate to severe OSA. This Phase 2 study (OB-204) was a single-center, randomized, double-blind, placebo-controlled parallel group trial including 45 obese men and women (BMI 30 to 40 kg/m2 inclusive), 30 to 65 years of age with OSA (apnea-hypopnea index, or AHI, greater than or equal to 15 at baseline who had not been treated with, or who were not compliant with CPAP, within three months of screening. Patients were randomized to placebo or top dose Qsymia. We are currently contemplating the timing of a Phase 3 study."
Sentiment: Strong Buy
The long-term upward trend of the market works against you (yes, believe it or not, markets used to go up most of the time).
Gains are taxed at the highest short-term rate.
It generally requires many more investment decisions, thereby increasing the chances of making a serious mistake.
It's a short-term, high-stress, trading-oriented style of investing that requires constant oversight.
Mistakes hurt your portfolio more as they compound. If you make a mistake with a long position, it becomes a smaller percentage of your portfolio as it drops. A mistaken short, however, grows larger as it appreciates.
If you go public with your short thesis, a company can attack you in many ways: file a lawsuit (Fairfax (OTCQB:FRFHF)), complain to regulators (who occasionally investigate) (MBIA (NYSE:MBI), Farmer Mac (NYSE:AGM)), tap your phone (Allied Capital (NYSE:AFC)), etc. Also, expect to get flamed on message boards and in the media. Many people view short selling as evil and un-American.
Your upside is capped, and your downside is unlimited - precisely the opposite of long positions. When shorting stocks, you could be right 80% of the time, but the losses from the 20% of the time that you're wrong could exceed the accumulated profits. Worse yet, a once-a-century storm - such as the internet bubble - might wipe you out entirely. If there's even a 1% annual risk of such an event, that tiny risk translates into a 39.5% chance of the freak event occurring over 50 years.
To prevent such an occurrence, most short sellers use stop loss limits, meaning they will start covering the short if it runs against them a certain amount. This means short sellers not only have to be right about a stock, but also about the timing. If a stock rises significantly, many short sellers will lock in losses, even if they are later proven correct.
In order to short a stock, you first must get the borrow from your broker, who has the power to call in the stock you've borrowed at any time - or worse yet, buy stock to cover for you. Brokers are most likely to do these things if the stock is rising quickly, and they're probably doing it to other short sellers as well at the same time, so all of this buying pressure can cause a stock to rise even further, triggering even more covering. This vicious cycle is called a "short squeeze", and it isn't pretty - we can show you the scars on our backs.
Wall street bankers know how to deal with the shorts.
Your idea is great !!!
Management does not need $300 million in the bank.
$200 million is enough.
Selling the company to big pharma is a good idea.
On what value ?
To who ?
There is only one company on my head and it is ENDP.
But ENDP just bought AUXL...
Stendra/Spendra could generate $ 1 billion in revenues on annual basis within 3 years.
The 15 minutes faster onset of action claims gives the product hug advantage Vs
From my old age with 30 years in the biopharma analysis I can say "You are good analyst" .
God save Israel
20% in royalties if revenues over 150 million.
15%-17% in royalties for 75-150 million.
12.50% -14.75% in royalties 1 - 74 million
Stendra sells $300 million 20% goes to VVUS ( royalties ) = $ 60
Spendra sells $150 million 17% goes to VVUS ( royalties ) = $ 25.50
Stendra milestone = $ 30
Spendra milestone = $ 10
Rest of the world ( royalties) = $ 10
Rest of the world milestone = $ 5
From Stendra & Spendra shipment at $400 million value 10% goes to VVUS = $ 40
VVUS totla income from Stendra/Spendra $180 million
Shorts can kiss my buttocks.
Sentiment: Strong Buy